What are the indications for angiotensin‑converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) in chronic kidney disease, when are they not beneficial, and are they indicated in stage 5 chronic kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ACEi/ARB Use in CKD: Clear Indications and Stage 5 Guidance

ACE inhibitors and ARBs are strongly indicated in CKD stages G1-G4 with albuminuria (particularly A2-A3), should be continued even when eGFR falls below 30 ml/min/1.73 m², but may need dose reduction or discontinuation in stage 5 CKD (eGFR <15) when uremic symptoms develop, uncontrolled hyperkalemia persists, or symptomatic hypotension occurs 1.

Primary Indications for ACEi/ARB in CKD

The 2024 KDIGO guidelines provide the most authoritative framework:

Strong Indications (Grade 1B-1A recommendations):

  • CKD stages G1-G4 with severely increased albuminuria (A3) - both with and without diabetes 1
  • CKD stages G1-G4 with moderately-to-severely increased albuminuria (A2-A3) in diabetic patients 1

Moderate Indications (Grade 2C recommendation):

  • CKD stages G1-G4 with moderately increased albuminuria (A2) without diabetes 1

Additional Indications:

  • Hypertension in CKD - particularly when combined with albuminuria 2
  • Heart failure with reduced ejection fraction - even without significant albuminuria 1
  • Normal to mildly increased albuminuria (A1) - for specific cardiovascular indications like hypertension or heart failure 1

Critical Implementation Points

Dosing strategy: Use the highest approved tolerated dose, as trial benefits were achieved at these doses 1. This is not a "start low, go slow" situation when the indication is clear.

Monitoring protocol: Check BP, serum creatinine, and potassium within 2-4 weeks of initiation or dose increase 1. This tight monitoring window is essential for safety.

Acceptable creatinine rise: Continue therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 1. A modest rise is expected and acceptable.

When ACEi/ARB Are NOT Beneficial or Should Be Avoided

Absolute Contraindications:

  • Combination therapy with ACEi + ARB + direct renin inhibitor - increases adverse events without additional benefit 2
  • Pregnancy - teratogenic effects (general medical knowledge)

Situations Requiring Dose Reduction or Discontinuation:

According to KDIGO 2024, consider reducing dose or stopping in these specific scenarios 1:

  1. Symptomatic hypotension - not just low numbers, but actual symptoms
  2. Uncontrolled hyperkalemia despite medical management - after attempting potassium-lowering strategies
  3. Stage 5 CKD (eGFR <15) with uremic symptoms - to reduce uremic burden while treating kidney failure

Important caveat: Hyperkalemia alone should NOT automatically trigger discontinuation. The guidelines explicitly state that hyperkalemia can often be managed with potassium-lowering measures rather than stopping the RASi 1. This includes dietary modification, diuretics, potassium binders, or newer agents.

Stage 5 CKD (eGFR <15): The Nuanced Answer

The evidence supports continuation of ACEi/ARB even in advanced CKD, including when eGFR falls below 30 ml/min/1.73 m² 1. The 2024 KDIGO guidelines explicitly state: "Continue ACEi or ARB in people with CKD even when the eGFR falls below 30 ml/min per 1.73 m²" 1.

For Stage 5 CKD specifically:

  • Default position: Continue therapy if already established and tolerated
  • Consider discontinuation only when:
    • Uremic symptoms develop that may be reduced by stopping RASi 1
    • Symptomatic hypotension occurs
    • Hyperkalemia becomes unmanageable despite aggressive treatment

Recent evidence from the STOP-ACEi trial (referenced in 3) showed that discontinuing RASi in advanced CKD did not slow eGFR decline or reduce mortality, while continuation showed a numerical trend toward lower ESKD rates. This supports the guideline recommendation to continue therapy.

Practical Algorithm for Stage 5 CKD:

  1. If patient is stable on ACEi/ARB: Continue therapy
  2. Monitor closely: Potassium, creatinine, BP, uremic symptoms
  3. If hyperkalemia develops: Implement potassium-lowering strategies first (dietary restriction, diuretics, potassium binders)
  4. If symptomatic hypotension: Consider dose reduction before complete discontinuation
  5. If uremic symptoms worsen: Consider dose reduction or discontinuation as part of conservative kidney management
  6. If starting dialysis (KRT): Reassess need, but continuation is reasonable if tolerated

Common Pitfalls to Avoid

Pitfall #1: Stopping ACEi/ARB prematurely when creatinine rises <30% - this modest rise is expected and represents hemodynamic changes, not kidney injury 1.

Pitfall #2: Discontinuing for hyperkalemia without attempting management strategies - potassium binders, dietary modification, and diuretics should be tried first 1.

Pitfall #3: Using submaximal doses - the renoprotective and cardiovascular benefits were demonstrated at target doses in clinical trials 1.

Pitfall #4: Avoiding initiation in stage 4 CKD - the guidelines support continuation even below eGFR 30, so starting in stage 4 is appropriate with proper monitoring 1.

Pitfall #5: Combining ACEi with ARB - this dual blockade increases adverse events without additional benefit and is explicitly not recommended 2.

The Bottom Line on Stage 5

ACEi/ARB remain indicated in stage 5 CKD unless specific complications arise 1. The threshold for discontinuation is high: unmanageable hyperkalemia despite treatment, symptomatic hypotension, or worsening uremic symptoms where stopping may provide relief. The default should be continuation with close monitoring, not automatic discontinuation based on eGFR alone.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.